ft 19 oct 94 tagamet us sale fall 76 quarter smithklin beecham new drug offset loss patent us sale tagamet smithklin beecham best sell drug collaps 76 per cent third quarter pound 31m expiri may patent protect ulcer remedi mr jan leschli chief execut anglo us drug group admit yesterday fall dramat said total unexpect said sale declin recent patent expiri drug compani compar third quarter figur show tagamet weak partli offset new drug sale rose 83 per cent constant exchang rate pound 124m pound 226m smithklin claim shingl drug famvir launch uk januari 30 per cent market share disput wellcom maker market leader zovirax said famvir 15 per cent market total sale 8 per cent higher pound 1 59bn pound 1 46bn trade profit similar amount pound 301m pound 277m pre tax profit 2 per cent pound 291m pound 285m 1993 quarter includ except pound 14m gain earn per share 4 per cent higher 7 8p help sharp fall estim full year tax charg 30 7 per cent 27 9 per cent partli result tax break aris dollar 2 3bn pound 1 5bn acquisit us distributor diversifi pharmaceut servic may quarterli dividend 3p per london quot share 30 16 cent per new york quot equiti unit adr compani four busi area pharmaceut grew slowest 3 per cent rise revenu came entir volum gain trade profit fell 2 per cent result lower contribut tagamet smithklin biggest seller antibiot augmentin saw sale rise 7 per cent pound 160m fastest growth came new anti depress seroxat call paxil us whose sale doubl pound 87m anim health sale rose 10 per cent thank anti infect treatment consum healthcar includ non medic product soft drink ribena lucozad 9 per cent increas sale sale clinic laboratori rose 5 per cent spite declin averag price lex page 24 merck eli lilli result page 31